191 related articles for article (PubMed ID: 36093087)
21. Saliva‑microbiome‑derived signatures: expected to become a potential biomarker for pulmonary nodules (MCEPN-1).
Ren Y; Ma Q; Zeng X; Huang C; Tan S; Fu X; Zheng C; You F; Li X
BMC Microbiol; 2024 Apr; 24(1):132. PubMed ID: 38643115
[TBL] [Abstract][Full Text] [Related]
22. Incidence of salivary side effects after radioiodine treatment using a new specifically-designed questionnaire.
Moreddu E; Baumstarck-Barrau K; Gabriel S; Fakhry N; Sebag F; Mundler O; Chossegros C; Taïeb D
Br J Oral Maxillofac Surg; 2017 Jul; 55(6):609-612. PubMed ID: 28456449
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
van Velsen EFS; Visser WE; van den Berg SAA; Kam BLR; van Ginhoven TM; Massolt ET; Peeters RP
Thyroid; 2020 Apr; 30(4):580-587. PubMed ID: 31928168
[No Abstract] [Full Text] [Related]
24. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up.
Wu JQ; Feng HJ; Ouyang W; Sun YG; Chen P; Wang J; Xian JL; Huang LH
Nucl Med Commun; 2015 Aug; 36(8):819-26. PubMed ID: 25932534
[TBL] [Abstract][Full Text] [Related]
25. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
[TBL] [Abstract][Full Text] [Related]
26. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma.
Alexander C; Bader JB; Schaefer A; Finke C; Kirsch CM
J Nucl Med; 1998 Sep; 39(9):1551-4. PubMed ID: 9744341
[TBL] [Abstract][Full Text] [Related]
27. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
28. Risk Factors of
Hollingsworth B; Senter L; Zhang X; Brock GN; Jarjour W; Nagy R; Brock P; Coombes KR; Kloos RT; Ringel MD; Sipos J; Lattimer I; Carrau R; Jhiang SM
J Clin Endocrinol Metab; 2016 Nov; 101(11):4085-4093. PubMed ID: 27533304
[TBL] [Abstract][Full Text] [Related]
29. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E
J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401
[TBL] [Abstract][Full Text] [Related]
30. Dysbiotic salivary microbiota in dry mouth and primary Sjögren's syndrome patients.
Rusthen S; Kristoffersen AK; Young A; Galtung HK; Petrovski BÉ; Palm Ø; Enersen M; Jensen JL
PLoS One; 2019; 14(6):e0218319. PubMed ID: 31211815
[TBL] [Abstract][Full Text] [Related]
31. Salivary gland function in thyroid cancer patients with radioiodine administration history.
Krcalova E; Horacek J; Gabalec F; Zak P; Dolezal J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Sep; 164(3):277-283. PubMed ID: 31223135
[TBL] [Abstract][Full Text] [Related]
32. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
33. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
[TBL] [Abstract][Full Text] [Related]
34. Oral microbiome and pancreatic cancer.
Wei AL; Li M; Li GQ; Wang X; Hu WM; Li ZL; Yuan J; Liu HY; Zhou LL; Li K; Li A; Fu MR
World J Gastroenterol; 2020 Dec; 26(48):7679-7692. PubMed ID: 33505144
[TBL] [Abstract][Full Text] [Related]
35. Gut microbiota changes and its potential relations with thyroid carcinoma.
Yu X; Jiang W; Kosik RO; Song Y; Luo Q; Qiao T; Tong J; Liu S; Deng C; Qin S; Lv Z; Li D
J Adv Res; 2022 Jan; 35():61-70. PubMed ID: 35003794
[TBL] [Abstract][Full Text] [Related]
36. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
37. Alterations in the gut microbiota and metabolite profiles of thyroid carcinoma patients.
Feng J; Zhao F; Sun J; Lin B; Zhao L; Liu Y; Jin Y; Li S; Li A; Wei Y
Int J Cancer; 2019 Jun; 144(11):2728-2745. PubMed ID: 30565661
[TBL] [Abstract][Full Text] [Related]
38. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment.
Caglar M; Tuncel M; Alpar R
Clin Nucl Med; 2002 Nov; 27(11):767-71. PubMed ID: 12394122
[TBL] [Abstract][Full Text] [Related]
39. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
Chow SM; Yau S; Lee SH; Leung WM; Law SC
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
[TBL] [Abstract][Full Text] [Related]
40. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
